During the last decades, the prevalence of allergy has dramatically increased. Allergen-specific
immunotherapy is the only currently available medical intervention that has the potential
to affect the natural course of the disease, but there are still many questions and
unmet needs hindering its widespread use to fulfill its treatment potential and maximize
its benefits for the society. To provide a comprehensive phenome-wide overview in
sublingual immunotherapy, using ragweed allergy as a target, we planned and carried
out a longitudinal, prospective, observational, open-label study (DesensIT). In this
paper we present challenges of using deep and comprehensive phenotypes embracing biological,
clinical and patient-reported outcomes in allergen-specific immunotherapy and show
how we designed the DesensIT project to optimize data collection, processing and evaluation.
